Amgen Hit With FDA Warning Over Drug-Device Combos
Law360, New York (February 11, 2014, 8:02 PM EST) -- The U.S. Food and Drug Administration on Tuesday released warning letters chastising Amgen Inc. for alleged design shortcomings related to prefilled syringes and Baxter Healthcare Corp. for the way it responded to complaints about certain medical devices.
In the letter to Amgen, regulators focused on syringes of osteoporosis drug Prolia and arthritis drug Enbrel, as well as vials of Enbrel with so-called vial adapters. One problem uncovered during a June inspection was that Amgen started sales of Prolia in 2010 before carrying out so-called design validation procedures that are intended to ensure a product was manufactured in accordance with its specifications, the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!